Skip to main content

Table 2 Efficacy of microRNAs in the differential diagnosis of pancreatic cancer from healthy participants

From: Advances in biomarkers and techniques for pancreatic cancer diagnosis

Study

MicroRNAs

source

Diagnostic power

AUC

Sensitivity

Specificity

Accuracy

Training

Validation

Training

Validation

Training

Validation

Training

Validation

Schultz et al

Panel I

Blood

0.86

0.83

0.85

0.85

0.64

0.48

0.74

0.72

Panel I + C*

Blood

0.93

0.94

0.85

0.85

0.95

0.98

0.90

0.89

Panel II

Blood

0.93

0.82

0.85

0.85

0.85

0.55

0.85

0.75

Panel II + C*

Blood

0.97

0.93

0.85

0.85

0.98

0.90

0.92

0.86

Zou et al

Six‐miRNA panel

Serum

0.910

0.978

0.953

0.933

0.767

0.96

  

Yu et al

miR-25

Serum

 

0.939

 

0.825

 

0.9364

 

0.8895

miR-25 + C*

Serum

 

0.985

 

0.975

 

0.9011

 

0.9895

Debernardi et al

miR-143

Urine

 

0.862

 

0.833

 

0.885

  

miR-143 + miR-30

Urine

 

0.923

 

0.833

 

0.962

  

Yang et al

miR-21 + miR-155

Stool

 

0.8111

 

0.9333

 

0.6667

  

miR-21 + miR-155 + miR-216

Stool

 

0.8667

 

0.8333

 

0.8333

  

Machida et al

miR-1246

Salivary

 

0.814

 

0.667

 

1.0

  

miR-4644

Salivary

 

0.763

 

0.750

 

0.769

  

miR-1246 + 4644

Salivary

 

0.833

 

0.833

 

0.923

  
  1. C* = CA19-9. Panel I is composed of miR-145, miR-150, miR-223, miR-636; Panel II is composed of miR-26b, miR-34a, miR-122, miR-126, miR-145, miR-150, miR-223, miR-505, miR-636, miR-885-5p; six‐miRNA panel contains let‐7b‐5p, miR‐192‐5p, miR‐19a‐3p, miR‐19b‐3p, miR‐223‐3p, and miR‐253p